Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Blood (2025) 146 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2025-5183

Published: 2025

Journal Articles

Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel, artificial intelligence-based technology

Blood (2025) 146 (Supplement 1): 2030.

https://doi.org/10.1182/blood-2025-2030

Published: 2025

Journal Articles

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Paola Guglielmelli, Francesca Crupi, Mirko Lomi, Francesco Mannelli, Jessica Caroprese, Niccolò Bartalucci, Stefano Soddu, Chiara Maccari, Alessio Enderti, Daniele Colazzo, leonardo Signori, Giada Rotunno, Alfonso Piciocchi, Giuseppe Gaetano Loscocco, Sara Bianchini, Elena Nacca, Paola Fazi, Marco Vignetti, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 3751.

https://doi.org/10.1182/blood-2025-3751

Published: 2025

Journal Articles

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2025-1025

Published: 2025

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Elisabetta Todisco, Ivana Lotesoriere, Federico Lussana, Valentina Mancini, Federica Gigli, Cristina Papayannidis, Michela Rondoni, Felicetto Ferrara, Sara Mastaglio, Annalina Piccioni, Michelina Dargenio, Andrea Corbingi, Francesco Mannelli, Alessandro Cignetti, Patrizia Zappasodi, Maria Paola Martelli, Monia Lunghi, Luana Fianchi, Patrizia Chiusolo, Francesco Grimaldi, Federica Pilo, Carla Fili, Debora Capelli, Massimo Breccia, Monica Bocchia, Monica Fumagalli, Sara Galimberti, Luca Maurillo, Calogero Vetro, Alessandra Sperotto, Caterina Patti, Erika Borlenghi, Federica Lessi, Alessandro Isidori, Raffaele Palmieri, Caterina Alati, Samuele Gatani, Chiara Pessina, Paola Minetto, Carola Riva, Marco Frigeni, Nicola Stefano Fracchiolla, Carla Mazzone, Marco Cerrano, Massimo Bernardi, Michele Gottardi, Roberto Cairoli, Adriano Venditti, Livio Pagano, Roberto Lemoli, Fabio Guolo

Blood (2025) 146 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2025-4608

Published: 2025

Journal Articles

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Blood (2025) 146 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2025-5243

Published: 2025

Journal Articles

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Blood (2024) 144 (Supplement 1): 65.

https://doi.org/10.1182/blood-2024-198342

Published: 2024

Journal Articles

Optimizing Molecular Diagnosis of Systemic Mastocytosis in the Era of KIT Tyrosine Kinase Inhibitors: Results of a Survey and of a Nationwide Proficiency Control Round of KIT D816V Mutation Testing Promoted By the RIMA (Rete Italiana MAstocitosi) Association

Blood (2024) 144 (Supplement 1): 7640.

https://doi.org/10.1182/blood-2024-202485

Published: 2024

Journal Articles

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Blood (2023) 142 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2023-178599

Published: 2023

Journal Articles

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

Valentina Boldrini, Paola Guglielmelli, Giada Rotunno, Chiara Maccari, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Naseema Gangat, Ayalew Tefferi, Alessandro M. Vannucchi

Blood (2023) 142 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2023-189571

Published: 2023

Journal Articles

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Blood (2023) 142 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2023-173574

Published: 2023

Journal Articles

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Blood (2023) 142 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2023-181142

Published: 2023

Journal Articles

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4215.

https://doi.org/10.1182/blood-2023-184845

Published: 2023

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Paola Guglielmelli, Fiorenza Irushani Vanderwert, Simone Romagnoli, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Laura Calabresi, Giulia Gentili, Giada Rotunno, Niccolò Bartalucci, Valentina Boldrini, Emanuela Sant'Antonio, Danilo Tarantino, Marco Pieraccioli, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 832–833.

https://doi.org/10.1182/blood-2022-156776

Published: 2022

Journal Articles

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

Paola Guglielmelli, Barbara Mora, Francesca Gesullo, Francesco Mannelli, Giuseppe Gaetano Loscocco, Leonardo Signori, Chiara Pessina, Fabiana Pancani, Ilaria Colugnat, Raffaela Aquila, Elena Nacca, Paolo Cicogna, Francesco Passamonti, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 1788–1789.

https://doi.org/10.1182/blood-2022-156781

Published: 2022

Journal Articles

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Blood (2022) 140 (Supplement 1): 9685–9687.

https://doi.org/10.1182/blood-2022-156371

Published: 2022

Journal Articles

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

Giuseppe Gaetano Loscocco, Raffaella Santi, Carmela Mannarelli, Francesco Mannelli, Francesca Gesullo, Giacomo Coltro, Paola Guglielmelli, Umberto Gianelli, Alessandro M Vannucchi

Blood (2022) 140 (Supplement 1): 9714–9716.

https://doi.org/10.1182/blood-2022-167880

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel, artificial intelligence-based technology

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Optimizing Molecular Diagnosis of Systemic Mastocytosis in the Era of KIT Tyrosine Kinase Inhibitors: Results of a Survey and of a Nationwide Proficiency Control Round of KIT D816V Mutation Testing Promoted By the RIMA (Rete Italiana MAstocitosi) Association

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only